CDK4 and neoplasm: Combinations of CDK4/6 inhibitor with hormonal therapy in patients with HR+ breast cancer enhanced the inhibition of tumor development and progress free survival in clinical trial [26, 27, 29] and have been approved by FDA for the treatment of metastatic HR+ breast cancer.